Patients’ Experiences of Atopic Dermatitis and Nemolizumab Treatment: An In-Trial Interview Study Embedded in a Phase 3 Clinical Trial (ARCADIA)
Authors:
Open Access
- 13 May 2025
- journal article
- research article
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
- Vol. 18 (5) , 511-521
Abstract
Background Patients with atopic dermatitis (AD) often experience a multitude of interrelated symptoms and impacts linked to the cardinal symptom of itch. Individual patient-reported outcome measures do not on their own reflect the complex physical and psychosocial burden experienced by patients with AD. This manuscript describes a qualitative in-trial interview substudy embedded in a phase 3 trial of nemolizumab in adults and adolescents with moderate-to-severe AD (ClinicalTrials.gov NCT03985943) and supplements evidence gathered during the core clinical trial. Methods Clinical trial participants enrolled at sites in Canada, Australia, Great Britain, and the USA were invited to the substudy. They participated in blinded telephone interviews within 2 weeks of treatment completion. Interviews were conducted in English using a semi-structured interview guide. They explored participants’ experiences of AD symptoms and impacts pre-trial and during the trial. Deidentified interview transcripts were coded and analyzed deductively following a content analysis approach. The interview sample was described using sociodemographic and key clinical trial data. Results A total of 73 participants reported 40 pre-trial symptoms, 10 of which affected more than half of the participants. Itch was simultaneously the most common pre-trial symptom and the symptom most commonly perceived as burdensome. Other common burdensome pre-trial symptoms were peeling/flaky/scaly skin (n = 9/43; 21%), skin redness (n = 8/43; 19%), painful skin and dry skin (n = 6/43; 14 % each), and burning sensation (n = 5/43; 12%). Itch was reported by 18% (n = 13/73) of participants to have caused other symptoms, and by a further 12% (n = 9/73) to have impacted their sleep. Participants reported 45 AD-related impact concepts across 6 health-related quality of life domains. Sleep disturbance (n = 20/52; 38%), emotions (n = 14/52; 27%), and daily activities (n = 12/52; 23%) were most often reported as being the most burdensome impact domains. More nemolizumab—than placebo-treated participants reported improvement of the 10 most common pre-trial AD symptoms and all 6 impact domains. More nemolizumab—than placebo-treated participants reported that the treatment helped manage their condition (n = 37/46; 80% versus n = 15/27; 56%), met their expectations (n = 32/46; 70% versus n = 15/27; 56%), and that they would recommend it to others (n = 41/46; 89% versus n = 20/27; 74%). Conclusions This qualitative study captures the heterogeneous symptoms and impacts of AD and highlights the perceived interrelatedness of itch and other AD symptoms and impacts. Our results show that alleviation of itch via targeted treatment may also reduce the complex physical and psychosocial burden of patients with moderate-to-severe AD, underscoring nemolizumab’s potential as a valuable addition to existing AD treatments. Trial Registration Clinicaltrials.gov NCT03985943. Registered 11 June 2019, https://clinicaltrials.gov/study/NCT03985943Keywords
Funding Information
- Galderma
This publication has 25 references indexed in Scilit:
- Treatment Preference Research in Atopic Dermatitis: A Systematic Review of Quantitative StudiesThe Patient - Patient-Centered Outcomes Research, 2024
- Publication Trends of Qualitative Research in DermatologyJAMA Dermatology, 2023
- What’s New in Topicals for Atopic Dermatitis?American Journal of Clinical Dermatology, 2022
- Burden of Moderate to Severe Atopic Dermatitis in Adults from France, Italy, and the UK: Patient-Reported Outcomes and Treatment PatternsDermatology and Therapy, 2022
- Nemolizumab: un innovador tratamiento biológico para el control de la interleuquina 31 (IL-31) clave en la dermatitis atópica y el prurigo nodularActas Dermo-Sifiliograficas, 2022
- Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative studyArchives of Dermatological Research, 2022
- Comorbidities and the impact of atopic dermatitisAnnals of Allergy, Asthma & Immunology, 2019
- A Comprehensive Conceptual Model of the Experience of Chronic Itch in AdultsAmerican Journal of Clinical Dermatology, 2018
- Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic ReviewDermatology and Therapy, 2017
- Disease severity, scratching, and sleep quality in patients with atopic dermatitisJournal of the American Academy of Dermatology, 2008